Patents Assigned to Allergan Sales, Inc., Allergan Botox Limited
  • Recombinant botulinum toxins with a soluble C-terminal portion
    Publication number: 20040253673
    Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.
    Type: Application
    Filed: December 5, 2003
    Publication date: December 16, 2004
    Applicant: Allergan Sales, Inc., Allergan Botox Limited
    Inventor: James A. Williams
  • Soluble recombinant botulinum toxins having a C-terminal portion of a heavy chain, a N-terminal portion of a heavy chain and a light chain
    Publication number: 20040219637
    Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.
    Type: Application
    Filed: December 5, 2003
    Publication date: November 4, 2004
    Applicant: Allergan Sales, Inc. Allergan Botox Limited
    Inventor: James A. Williams
  • Recombinant botulinum toxins having a soluble C-terminal portion of a heavy chain, an N-terminal portion of a heavy chain and a light chain
    Publication number: 20040142455
    Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.
    Type: Application
    Filed: December 5, 2003
    Publication date: July 22, 2004
    Applicant: Allergan Sales, Inc., Allergan Botox Limited
    Inventor: James A. Williams
  • Recombinant botulinum toxins with a soluble C-terminal portion, an N-terminal portion and a light chain
    Publication number: 20040115215
    Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.
    Type: Application
    Filed: December 5, 2003
    Publication date: June 17, 2004
    Applicant: Allergan Sales, Inc., Allergan Botox Limited
    Inventor: James A. Williams
  • Soluble recombinant botulinum toxins
    Publication number: 20030219457
    Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.
    Type: Application
    Filed: October 15, 2002
    Publication date: November 27, 2003
    Applicant: Allergan Sales, Inc., Allergan Botox Limited
    Inventor: James A. Williams